NDAORALSUSPENSION
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
15
Data completeness
6/8 — Strong
FLEQSUVY (baclofen) by R-Pharm US is gaba a agonists [moa]. First approved in 2022.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLEQSUVY is an oral suspension formulation of baclofen, a GABA-A agonist approved in February 2022 for muscle spasticity and related conditions. It works by enhancing inhibitory neurotransmission in the central nervous system to reduce muscle tone and spasticity. This suspension formulation offers an alternative delivery method to traditional tablets for patients with swallowing difficulties or dosing flexibility needs.
$0.831MPart D
Peak11.3 years to LOEProduct is at peak lifecycle stage with modest Medicare Part D penetration (398 claims in 2023), indicating a stable but limited commercial footprint requiring focused market development.
Mechanism of Action
GABA A Agonists
Pharmacologic Class:
gamma-Aminobutyric Acid-ergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Intrathecal Baclofen and Pediatric Dystonia
Started Nov 2024
65 enrolled
Dystonic Cerebral Palsy
A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers
Started Jan 2017
40 enrolled
Healthy Volunteers
Intrathecal (IT) Baclofen Drug Distribution
Started Apr 2016
27 enrolled
Muscle Spasticity
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
Started Sep 2015
18 enrolled
Alcohol Use Disorder
Intrathecal Baclofen (ITB) Bolus on Neuropathic Pain (NP). Preliminary Study.
Started Dec 2014
12 enrolled
Neuropathic Pain
Worked on FLEQSUVY at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.